Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
39 hedge funds and large institutions have $28.9M invested in Cidara Therapeutics in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 11 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
9% more capital invested
Capital invested by funds: $26.6M → $28.9M (+$2.28M)
0.27% less ownership
Funds ownership: 2.97% → 2.7% (-0.27%)
13% less funds holding
Funds holding: 45 → 39 (-6)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$221K |
| 2 |
DMK
David M. Knott
|
+$113K |
| 3 |
Renaissance Technologies
New York
|
+$109K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$82.4K |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$58.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$603K |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$481K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$407K |
| 4 |
Millennium Management
New York
|
-$318K |
| 5 |
AC
Aisling Capital
New York
|
-$218K |
CDTX Hedge Fund Activity: Q3 2019 in Review
39 of the 4,573 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q3 2019, worth a combined $28.9M — up 8.6% from $26.6M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CDTX and 5 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was Omega Fund Management, adding an estimated $221K. The largest seller was Prosight Management, exiting entirely with an estimated $603K sold.
- 39 institutional investors held Cidara Therapeutics (CDTX) as of Q3 2019, down from 45 in Q2 2019.
- Funds reported $28.9M of Cidara Therapeutics stock for Q3 2019, up 8.6% quarter-over-quarter.
- 5 funds opened new Cidara Therapeutics positions in Q3 2019 and 11 closed out, a net change of -6 holders.
- The largest Cidara Therapeutics buyer in Q3 2019 was Omega Fund Management, an estimated $221K added.
- The largest Cidara Therapeutics seller in Q3 2019 was Prosight Management, an estimated $603K sold.
Based on aggregated 13F filings for Q3 2019.